The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs

Author： Hoffmann Michael M   Winkelmann Bernhard R   Wieland Heinrich   März Winfried  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.2, Iss.2, 2001-05, pp. : 107-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

New prospects for lipid-lowering drugs

By Thompson G.R.   Naoumova R.P.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 715-727

Informa Healthcare

Access to resources Recommend Favorite

Emerging lipid-lowering drugs: squalene synthase inhibitors

By Elsayed Raghda K   Evans Jeffery D  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 309-322

Informa Healthcare

Access to resources Recommend Favorite

Patients are less likely to receive lipid-lowering drugs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 371, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

A New Class of Lipid-Lowering Drugs: Ezetimibe

By  

Heart Drug, Vol. 3, Iss. 4, 2004-02 ,pp. : 214-216

Karger

Access to resources Recommend Favorite

Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract

By  

Current Pharmaceutical Design, Vol. 15, Iss. 5, 2009-02 ,pp. : 490-516

Bentham Science Publishers

Access to resources Recommend Favorite